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JCB: Feature
As is true for many fields of research, cell biology has always 
been propelled forward by technological innovations (Botstein, 
2010). Thanks to these advances we now have access to micro­
scopes and other equipment with exquisite resolution and sen­
sitivity, a variety of methods to track and quantify biological 
molecules, and many ingenious tools to manipulate genes, mol­
ecules, organelles, and cells. In addition, we have hardware and 
software that enable us to analyze our data, and build models of 
cells and their components.
Naturally, even today’s technologies have limitations, and 
hence there is always need for improvements and for completely 
novel approaches that create new opportunities. Cell biology 
is one of the research areas with many chances for individual 
young scientists to invent and develop such new technologies. 
Numerous recent examples illustrate that such “bottom­up” efforts 
can be highly successful across all areas in cell biology; e.g., 
as a handy vector for RNA interference (Brummelkamp et al., 
2002); as methods for visualization of protein–protein or protein– 
DNA interactions (Roux et al., 2012; Kind et al., 2013); as 
tools to study chromatin (van Steensel et al., 2001), ribonucleo­
protein complexes (Ule et al., 2003), or translation (Ingolia 
et al., 2009); or as tags for sensitive protein detection (Tanenbaum 
et al., 2014), just to name a few examples.
As a student or postdoc, you may similarly conceive an 
idea for a new method or tool. Usually this idea is inspired by 
a biological question that you are trying to address in your 
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ongoing research project. You might then also realize that the 
new method, at least on paper, may have additional applications. 
Yet, the development of a new technique typically requires a sub­
stantial effort. Should you halt or delay your ongoing research 
and embark on the development of this new technique? And if 
so, what is the best strategy to minimize the risks and maxi­
mize the chance of success? How do you get the most out of the 
investment that it takes to develop the method? Here I will dis­
cuss some issues that students and postdocs might want to con­
sider when venturing into the development of a new technique.
To develop or not to develop
Development of a new technique can take one to five years of 
full­time effort, and hence can be a risky endeavor for a young 
scientist. The decision to start such a project therefore requires 
careful weighing of the pros and cons (see text box). In essence, 
there are four main considerations.
First, conduct a thorough literature survey to ensure that 
the method has not been developed by others already, and to 
search for indications that the method may or may not work. 
The second consideration is the potential impact of the new 
technology. Impact is often difficult to predict, but it is linked 
to how broadly applicable the technology will be. Will the new 
technology only provide an answer to your specific biological 
question, or will it be more widely applicable? It may be helpful 
to ask: how many other scientists will be interested in using the 
technology, or at least will profit substantially from the result­
ing biological data or knowledge? If the answer is “about five,” 
then the impact will likely be low; if the answer is “possibly 
hundreds,” then it will certainly be worth the investment. This 
potential impact must be balanced against the third consider­
ation, which is the estimated amount of time and effort it takes 
to develop the technology. The fourth major consideration is: 
What is the chance that my technique will actually work and 
what is the risk of failure? There is no general answer to this 
question, but below I will outline strategies to reduce the risk of 
failure and minimize the associated loss of time and effort. For 
this I will consider the common phases of technology develop­
ment (Fig. 1).
New technologies drive progress in many research fields, 
including cell biology. Much of technological innovation 
comes from “bottom-up” efforts by individual students 
and postdocs. However, technology development can be 
challenging, and a successful outcome depends on many 
factors. This article outlines some considerations that are 
important when embarking on a technology development 
project. Despite the challenges, developing a new tech-
nology can be extremely rewarding and could lead to a 
lasting impact in a given field.
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Version 1.0: Reaping the first  
biological insights
During the optimization process it is helpful to define an end­
point that will result in “version 1.0” of the technology. Typi­
cally this is when the technology is ready to address its first 
interesting biological question. Once you have reached this 
point, it may be useful to temporarily refrain from further op­
timization of the technology, and focus on applying it to this 
biological question. This has two purposes. First, it subjects the 
technology to a real­life test that may expose some of its short­
comings, which then need to be addressed in further optimiza­
tion cycles. Second, it may yield biological data that illustrates 
the usefulness of the technology, which may inspire other 
scientists to adopt the method. If you are based in a strictly 
technology­oriented laboratory, collaboration with a colleague 
who is an expert in the biological system at hand may expedite 
this phase and help to work out bugs in the methodology.
If version 1.0 performs well in this biological test, it may 
be time to publish the method. For senior postdocs, this may 
also be a good moment to start your own laboratory. A new 
technology is usually a perfect basis for such a step.
Disseminating and leveraging  
the technology
When, upon publication, other scientists adopt your new tech­
nology, they will often implement improvements and new 
applications, which makes the technology attractive to yet more 
scientists. This snowball effect is one of the hallmarks of a high­
impact technology. An extreme example is the recently developed 
CRISPR–Cas9 technology (Doudna and Charpentier, 2014), 
for which improvements and new applications are currently 
reported almost on a weekly basis. What can you do to get such 
a snowball rolling?
First, it helps to publish the new technology in a widely read 
or Open Access journal, to present it at conferences, and to initiate 
collaborations in order to reach a broad group of potential users. 
Second, the threshold for others to use the new technology must be 
as low as possible. Thus, implementation of the technology must be 
simple, and users must have easy access to detailed protocols. 
A website with troubleshooting advice, answers to frequently 
asked questions, and (if applicable) software for download will 
also help. Depending on the complexity of the technology, it may 
be worth considering whether to organize hands­on training, per­
haps in the form of a short course. This may seem like a big invest­
ment, but it can substantially contribute to the snowball effect.
Third, materials and software required for the technology 
should be readily available. Technology transfer offices of re­
search institutes often insist on the signing of a material trans­
fer agreement (MTA) before materials such as plasmids can 
be shared. But all too often this leads to a substantial adminis­
trative burden and delays of weeks or even months. Free “no­
strings­attached” sharing of reagents is often the best way to 
promote your technology—and scientific progress in general.
Patents and the commercial route
Before publication of the technology, you may consider pro­
tecting the intellectual property by filing a patent application. 
Quick proof-of-principle
An adage that is often heard in the biotechnology industry is 
“fail fast.” It is OK if a project turns out to be unsuccessful, as 
long as the failure becomes obvious soon after the start. This 
way the lost investment will be minimal. In an academic setting, 
it may also be good to prevent finding yourself empty­handed 
after years of work. As a rule of thumb, I suggest that one should 
aim to obtain a basic proof­of­principle within approximately 
four months of full­time work. If after this period there still 
is no indication that the method may eventually work, then it 
may be wise to terminate the project, because further efforts are 
then also likely to be too time­consuming. It is thus advisable 
to schedule a “continue/terminate” decision point about four 
months after the start of the project—and stick to it. Note that at 
this stage the proof­of­principle evidence may be rudimentary, 
but it is crucial that it is convincing enough to be a firm basis for 
the next step: optimization.
Optimization cycles
Obtaining the first proof­of­principle evidence is a reason to 
celebrate, but usually it is still a long way toward a robust, gen­
erally applicable method. Careful optimization is required, 
through iterations of systematic tuning of parameters and test­
ing of the performance. This can be the most time­consuming 
phase of technology development. To keep the cycle time of the 
iterative optimizations short, it is essential that a quick, easy 
readout is chosen. This readout should be based on a simple 
assay that ideally requires no more than 1–2 d. It is important 
that the required equipment is readily accessible; for example, 
if for each iteration you have to wait for several weeks to get 
access to an overbooked shared FACS or sequencing machine, 
or if you depend on the goodwill of a distant collaborator who 
has many other things on his mind, then the optimization pro­
cess will be slow and frustrating. If your technology consists of 
a lengthy protocol with multiple steps, try to optimize each step 
individually (separated from the rest of the protocol), and in­
clude good positive and negative controls.
Remember that statistical analysis is your ally: it is a tool 
to distinguish probable signals from random noise and thus en­
ables you to make rational decisions in the optimization process 
(did condition A really yield better results than condition B?). 
Assays with quantitative readouts are easier to analyze statisti­
cally and are therefore preferable.
Points to consider before starting to develop a new technology.
•Literature search: Does a similar technology already exist? Is there 
published evidence for or against its feasibility?
•How much time and effort will it take?
•What is the chance of success?
•Are you in the right environment to develop the technology?
•Are simple assays available for testing and optimization?
•How important are the biological questions that can be addressed?
•How broadly applicable will the technology be?
•What are the advantages compared with existing methods?
•Is the timing right (will there be substantial interest in the technology)?
•Is there potential for future applications/modifications that will fur-
ther enhance the technology?
•How easy will it be for other researchers to use the technology?
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Most academic institutes do this, but often the associated costs 
are high and the ultimate profits uncertain, in part because it can 
be difficult to enforce protection of a patented technology (how 
do you prove that your technology was used by someone else?). 
That said, some technologies or associated materials may be 
more effectively scaled up and disseminated through a commer­
cial route than via purely academic channels. Specific compa­
nies may have distribution infrastructure or technical expertise 
that is hard to match in an academic laboratory. Founding your 
own company may also be a way to give the technology more 
leverage, as it provides access to funds not available in an aca­
demic setting. In these cases, timely filing of a patent application 
may be essential. Note that in certain countries one cannot apply 
for a patent once the technology has been publicly disclosed 
(e.g., at a conference).
Competing technologies
Often different technologies for the same purpose are invented 
independently and more or less simultaneously. It is there­
fore quite likely that sooner or later an alternative technology 
emerges in the literature, or appears on the commercial market. 
This is sometimes referred to as “competing technology,” but 
in an academic setting this is somewhat of a misnomer, as solid 
science requires multiple independent methods to cross­validate 
results. Moreover, it is extremely rare that two independent 
technologies cover exactly the same spectrum of applications. 
For example, one technology may have a higher resolution, but 
the other may be superior in sensitivity. The sudden emergence 
of a competing technology can however have strategic con­
sequences, and it is important to carefully define the advantages 
of your technology and focus on these strengths.
A bright future for technology development
New technologies generally consist of a new combination of 
available technologies, or apply newly discovered fundamental 
principles. Because the pool of available knowledge and tools 
continues to expand, the opportunities to devise and test new 
methods will only improve. This is further facilitated by the 
increasing quality of basic methods and tools to build on. Thus, 
there is a bright future for technology development. With a 
carefully designed strategy, the risks associated with such 
efforts can be minimized and the overall impact maximized. 
In the end, it is extremely gratifying to apply a “home­grown” 
technology to exciting biological questions, and to see other 
laboratories use it.
Figure 1. Flow diagram showing the typical phases of technology development.
